Trials / Completed
CompletedNCT02903095
Single Ascending Dose Study of TD-1439 in Healthy Subjects
A Phase 1, Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TD-1439 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- Theravance Biopharma · Industry
- Sex
- All
- Age
- 19 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
Single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TD-1439 in healthy subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TD-1439 | |
| DRUG | Placebo |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2016-12-01
- Completion
- 2017-02-01
- First posted
- 2016-09-16
- Last updated
- 2021-01-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02903095. Inclusion in this directory is not an endorsement.